What we know about the new coronavirus infection in cancer patients

The article presents data from a retrospective study of COVID-19 outcomes in cancer patients from 24 regions of the Russian Federation. The study included 1,055 patients who had a Coronavirus disease 2019, including 451 (42.7 %) men and 604 (57.3) women. The mean age was 58.7 years (29–90); 108 (10.2 %) patients were diagnosed with various comorbidities. 627 (59.4 %) were receiving antitumor drug therapy at the time of diagnosis of COVID-19, and 332 (31.5 %) received antitumor chemotherapy. Most patients had asymptomatic or mild COVID-19: asymptomatic in 205 (19.4 %) patients, and mild — in 517 (49.0 %) patients. Moderate / severe COVID-19 was observed in 268 (25.4 %) patients, while severe / critical COVID-19 was diagnosed in 65 (6.2 %). 1204601776 25 (2.4 %) patients died after COVID-19. The average age of cancer patients who died was 66.3 years (31–84). Among the deceased patients, 16 (64.0 %) were women and 9 (36.0 %) were men. To determine the factors increasing the risk of death in cancer patients we performed univariate and multivariate analyses. Conclusions: based on the presented data, the probability of death from COVID-19 was associated with the anti-tumor therapy administered during the disease. This conclusion obliges us to stop antitumor chemotherapy during the COVID-19 disease.

Authors

Institutions

Publication Details

Journal
Malignant tumours
Published
2025-01-22
DOI
https://doi.org/10.18027/2224-5057-2024-027
Primary Topic
COVID-19 and healthcare impacts
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

What we know about the new coronavirus infection in cancer patients

Sergei Tjulandin, Evgenia Kuzmina, A. A. Polyakov, Polina S. Feoktistova et al.
Malignant tumours
COVID-19 and healthcare impacts
article

What we know about the new coronavirus infection in cancer patients

Sergei Tjulandin, Evgenia Kuzmina, A. A. Polyakov, Polina S. Feoktistova, К. V. Menshikov, A. Z. Isyangulova, Mikhail Mazhbich, A. Tryakin, I.L. Shlivko, A. V. Fateeva, Lyudmila Zhukova, V. A. Khaylenko, М. Yu. Fedyanin, А. I. Stukan, Aleksandr Khryashchev, В. В. Саевец, Darija Volkova, Vera Karaseva, Yu. I. Murzina, E. E. Tonenkova, I. S. Chebykina, E. A. Azarova, A. A. Emelyanova, A. K. Iglamov, A. N. Igumnova
article en

Abstract

The article presents data from a retrospective study of COVID-19 outcomes in cancer patients from 24 regions of the Russian Federation. The study included 1,055 patients who had a Coronavirus disease 2019, including 451 (42.7 %) men and 604 (57.3) women. The mean age was 58.7 years (29–90); 108 (10.2 %) patients were diagnosed with various comorbidities. 627 (59.4 %) were receiving antitumor drug therapy at the time of diagnosis of COVID-19, and 332 (31.5 %) received antitumor chemotherapy. Most patients had asymptomatic or mild COVID-19: asymptomatic in 205 (19.4 %) patients, and mild — in 517 (49.0 %) patients. Moderate / severe COVID-19 was observed in 268 (25.4 %) patients, while severe / critical COVID-19 was diagnosed in 65 (6.2 %). 1204601776 25 (2.4 %) patients died after COVID-19. The average age of cancer patients who died was 66.3 years (31–84). Among the deceased patients, 16 (64.0 %) were women and 9 (36.0 %) were men. To determine the factors increasing the risk of death in cancer patients we performed univariate and multivariate analyses. Conclusions: based on the presented data, the probability of death from COVID-19 was associated with the anti-tumor therapy administered during the disease. This conclusion obliges us to stop antitumor chemotherapy during the COVID-19 disease.

Malignant tumoursVol. 14(4)
North-Eastern Federal University (RU), Pirogov Russian National Research Medical University (RU), Moscow Clinical Scientific Center (RU), Nizhny Novgorod Regional Clinical Oncology Center (RU), Ministry of Health of the Russian Federation (RU), Ministry of Health (SA), City Clinical Hospital (RU), City Clinical Hospital No. 2 (RU), Murmansk Regional Oncology Center (RU), Ministry of Health (TT), Angiologica (Italy) (IT), State Healthcare Institution "Regional Clinical Oncological Dispensary" (RU), Chelyabinsk Regional Clinical Oncology Center (RU)
Openalex Percentile: Top 98%
COVID-19 and healthcare impacts
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.